Therefore, here we test whether aberrant mucus gel structure, mucociliary clearance, and airway obstruction in asthma can be improved by disrupting mucin disulfides with the reducing agent tris(2-carboxyethyl)phosphine (TCEP) (Fig. 1b). The gene discussed is MUC5AC; the disease is asthma.